We are thrilled to announce that Dr. Jean-Pierre Bizzari has joined our Scientific Advisory Board. With a distinguished career in oncology and a wealth of experience in clinical development, Dr. Bizzari brings invaluable expertise to our team.
Dr. Bizzari holds a medical degree from the University of Nice in France and trained as an oncologist at the Pitie Salpetriere hospital in Paris. He furthered his training in Toronto at the Ontario Cancer Institute and in Montreal at the McGill Cancer Center before transitioning to the pharmaceutical industry in 1983. His first role was as Head of Oncology at the Institut de Recherches Internationales SERVIER in France.
In 1993, Dr. Bizzari joined Rhone-Poulenc Rorer as Vice President of Clinical Oncology, initially based in Paris before moving to Collegeville, Pennsylvania, USA, in 1997. Following the merger of Rhone-Poulenc Rorer with Hoechst Marion Roussel to form Aventis, he served as Vice President of Oncology Clinical Development. From April 2002 to September 2008, he was Vice President of Clinical Development, Oncology, at Sanofi-Aventis in Malvern, PA. In 2008, he joined Celgene as Executive Vice President, Clinical Development Oncology, where he remained until 2016.
Dr. Bizzari has played a pivotal role in the clinical development of several key anticancer agents, including:
Beyond these achievements, Dr. Bizzari has been involved in developing numerous other compounds, such as anti-angiogenics (VEGF-trap), gene therapy, vaccines, and bio-reductive agents.
His contributions to the scientific community are extensive, with more than 70 articles published in peer-reviewed journals and over 160 abstracts presented at scientific congresses. Dr. Bizzari’s research interests include the methodology of clinical trials and pharmacokinetics/pharmacodynamics (pk/pd) analysis.
Dr. Bizzari is a member of the Scientific Advisory Board of the French National Cancer Institute (INCa) and a board member of the European Organisation for Research and Treatment of Cancer (EORTC). Additionally, he serves on the Board of Directors for several biopharmaceutical companies, including Transgene SA, Halozyme Therapeutics, Nordic Nanovector, Pieris, Onxeo, and Compugen.
We are confident that Dr. Bizzari’s extensive experience and profound knowledge will greatly contribute to our mission and help drive our innovative research and development efforts.
© 2024 Casinvent